Viracta Therapeutics Inc. Common Stock
(NASDAQ:VIRX)
Description
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. It is developing nanatinostat, an oral combination therapy in combination with the antiviral agent valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma. The company was founded in 2007 and is headquartered in Cardiff, California.
VIRX Overview
None
Sector |
Health Care |
Industry |
Major Pharmaceuticals |
Previous Close |
$1.5313 |
Previous Close Volume |
40820 |
Latest News
- Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update 13 Nov 2024 07:07:22
- Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma 06 Nov 2024 16:35:16
- Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference 05 Sep 2024 11:35:08
- Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update 14 Aug 2024 07:08:53
- Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer 14 May 2024 07:54:32
- Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update 09 May 2024 16:24:44
- Viracta Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference 07 May 2024 16:25:05
- Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma 15 Apr 2024 08:25:10
- Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan 01 Apr 2024 17:55:20
- Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update 07 Mar 2024 17:25:11
- Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial 29 Feb 2024 08:10:35
- Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference 06 Feb 2024 16:10:43